Oral Presentation at ESMO will feature updated results from Phase 1/2 SPENCER study

Paris, France – October 16th, 2023

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced that updated data from its Phase 1/2 SPENCER study on EO2401 in combination with nivolumab, in patients with adrenal tumors, will be presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2023, to take place on October 20-23, 2023 in Madrid, Spain.

Oral Presentation details – Abstract 724O

Title: EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP); EOADR1-19/SPENCER

Presenter: Dr. Eric Baudin, Associate Professor and Head of the Endocrine Oncology Unit at Gustave Roussy (Villejuif, France)

Session Title: Proffered Paper Session – NETs and endocrine tumors

Presentation Date and Time: Sunday, October 22, 2023, at 9.30 am CET

Location: Toledo Auditorium – Hall 3

The abstract was published today and is available online in the ESMO Congress 2023 Abstract Book (a supplement to the official ESMO journal, Annals of Oncology).

About SPENCER

SPENCER (EOADR1-19) is a multicenter, open-label, first-in-human, Phase 1/2 study of EO2401 in combination with an immune checkpoint inhibitor (nivolumab) for the treatment of patients with locally advanced or metastatic adrenocortical carcinoma (ACC), or malignant pheochromocytoma/paraganglioma (MPP). The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of the combination at sites in Europe and the US.

For more information on the Phase 1/2 trial of EO2401 in adrenal tumors, please refer to ClinicalTrials.gov Identifier: NCT04187404

About EO2401

EO2401 is Enterome’s first-in-class off-the-shelf OncoMimics^™ peptide-based immunotherapy. It combines three microbial-derived OncoMimics^™ peptides that closely mimic specific cytotoxic T cell (CD8⁺ T cell) epitopes on the Tumor-Associated Antigens IL13Ra2, BIRC5, and FOXM1, combined with the helper peptide (CD4⁺ T cell epitope) Universal Cancer Peptide 2 (UCP2).

About OncoMimics^™

OncoMimics^™ immunotherapies are designed to activate pre-existing effector memory T cells that target bacterial (non-self) peptides, which are strongly cross-reactive against selected Tumor-Associated Antigens (TAAs), or B cell markers expressed on tumoral cells, resulting in a rapid, targeted cytotoxic response against cancer.

Download the press release (.pdf format)